VivoSeq
Cardiovascular

Orthostatic Hypotension

38

Pipeline Programs↗

7

Active Trials↗

21

Companies Involved↗

Orthostatic Hypotension is a moderately active landscape with 38 programs across 21 companies. The most active players are Kenvue Brands, Novartis, GSK. 7 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kenvue Brands

2 programs

Phase 1Novartis logo

Novartis

2 programs

Phase 1GSK logo

GSK

1 program

Phase 1M

Map77

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

39 of 40 classified programs — the dominant modality here.

3%ALL OTHERSPeptide13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 98% of 41 pipeline programs.

Analysis

Trial Status

36

clinical trials

Completed21 · 58%
Recruiting5 · 14%
Terminated5 · 14%
Unknown status3 · 8%
Enrolling by invitation1 · 3%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

36 trials

Treatment of Orthostatic Hypotension in SCI
Recruiting·JJames J. Peters Veterans Affairs Medical Center·Phase 4·NCT05839652·25 enrolled
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
Recruiting·VVanderbilt University Medical Center·Phase 1·NCT02429557·29 enrolled
Hypercapnia in Orthostatic Hypotension
Recruiting·UUniversity of Calgary·N/A·NCT05295810·80 enrolled
Automated Abdominal Binder for Orthostatic Hypotension
Recruiting·VVanderbilt University Medical Center·Phase 1/2·NCT03482297·31 enrolled
A Single-Blind Dose-Ranging Study in Subjects With Neurogenic Orthostatic Hypotension to Evaluate the Effect of CST-3056 on Symptoms and Signs of Orthostatic Hypotension
Recruiting·CCuraSen Therapeutics, Inc.·Phase 2·NCT07089043·12 enrolled
SalT Supplementation in Older Adults With Orthostatic Intolerance Disorders (STOOD): a Phase IIa Randomised Controlled Trial of Sodium Supplementation in Those Consuming Moderate Salt Intake.
Active, not recruiting·University of Galway·Phase 2·NCT06188663·42 enrolled
Droxidopa / Pyridostigmine in Orthostatic Hypotension
Enrolling by invitation·MMayo Clinic·Phase 2·NCT01370512·30 enrolled
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Completed·TTheravance Biopharma·Phase 2·NCT02705755·34 enrolled
The Pathophysiology of Orthostatic Hypotension
Completed·VVanderbilt University Medical Center·Phase 1·NCT00748059·10 enrolled
Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
Completed·JJames J. Peters Veterans Affairs Medical Center·Phase 2·NCT02307526·10 enrolled
Orthostatic Hypotension in Rehabilitation Patients
Completed·VVA Office of Research and Development·N/A·NCT00117585·341 enrolled
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Completed·UUniversity Hospital, Toulouse·Phase 2/3·NCT02071459·107 enrolled
Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Completed·Takeda logoTakeda·Phase 4·NCT01515865·98 enrolled
Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Completed·SSeoul National University Hospital·Phase 4·NCT02308124·87 enrolled
A Study for Patients With Neurogenic Orthostatic Hypotension
Completed·Takeda logoTakeda·Phase 4·NCT00046475·140 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)